anti-miR-182 antisense oligonucleotides (Regulus Therapeutics)

N/A

Report date: 2025/03/18 20:00:05
NME

Base Information

Drug Nameanti-miR-182 antisense oligonucleotides (Regulus Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisenseSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > microRNA
Mechanisms of ActionAntisense oligonucleotide inhibitorsMetastasis inhibitors
TargetsUpdating
Therapy Area/IndicationsNeoplasm Metastasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesRegulus Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesRegulus Therapeutics IncIonis Pharmaceuticals IncAlnylam Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNeoplasm Metastasis

Other Information

ATC CodeN/A
Related LinksN/A